Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland.

MLA

Adamczyk, Michał, et al. “Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland.” Journal of Clinical Medicine, vol. 12, no. 4, Feb. 2023, p. 1675. EBSCOhost, https://doi.org/10.3390/jcm12041675.

APA

Adamczyk, M., Bartosińska, J., Raczkiewicz, D., Adamska, K., Adamski, Z., Czubek, M., Kręcisz, B., Kłujszo, E., Lesiak, A., Narbutt, J., Noweta, M., Owczarczyk-Saczonek, A., Owczarek, W., Reich, A., Samotij, D., Siekierko, A., Szczęch, J., Walecka, I., Ciechanowicz, P., & Woźniacka, A. (2023). Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland. Journal of Clinical Medicine, 12(4), 1675. https://doi.org/10.3390/jcm12041675

Chicago

Adamczyk, Michał, Joanna Bartosińska, Dorota Raczkiewicz, Kinga Adamska, Zygmunt Adamski, Maria Czubek, Beata Kręcisz, et al. 2023. “Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland.” Journal of Clinical Medicine 12 (4): 1675. doi:10.3390/jcm12041675.